Efficacy and safety analysis of camrelizumab combined with lenvatinib in the treatment of patients with advanced liver cancer after local treatment
Objective To investigate the efficacy and safety of camrelizumab combined with lenvatinib in the treatment of patients with advanced liver cancer after local treatment.Methods The clinical data of patients with advanced liver cancer who were treated and followed up in a hospital from January 2021 to December 2022 were retrospectively collected for study.According to the treatment plan,these patients were divided into the test group(58 cases)and the control group(52 cases).The test group was treated with camrelizumab combined with lenvatinib,while the control group was treated with lenvatinib monotherapy.Both groups were treated for at least 42 days.The evaluation indicators included disease remission rate,survival time and adverse drug reactions.Results The objective remission rate(ORR)of the test group was 53.45%,which was higher than that of the control group(32.69%),and the disease control rate(DCR)was 79.31%,which was higher than that of the control group(57.69%)(P＜0.05).The follow-up time was 5 to 20 months,and the median follow-up time was 13.00(9.00,20.00)months.The overall survival(OS)and progression-free survival(PFS)of the test group were higher than those of the control group,and the total survival rate was higher than that of the control group(P＜0.05).The incidence of liver and kidney injury in the test group was higher than that in the control group(P＜0.05).Conclusion Camrelizumab combined with lenvatinib can improve the remission rate and prolong the survival time of patients with advanced liver cancer after local treatment,but it is easy to aggravate the liver and kidney damage during the treatment.
NETL
